ROIV (Roivant Sciences) Other Current Assets: $105.32 Mil (As of Mar. 2026)


ROIV Roivant Sciences Ltd ROIV
55 GF Score
Price $34.73
GF Value $10.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Other Current Assets?

Roivant Sciences ROIV +1.94% 55 Other Current Assets is $105.32 Mil as of Mar. 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $10.45 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Roivant Sciences's other current assets for the quarter that ended in Mar. 2026 was $105.32 Mil.

Roivant Sciences's quarterly other current assets increased from Sep. 2025 ($125.81 Mil) to Dec. 2025 ($129.91 Mil) but then declined from Dec. 2025 ($129.91 Mil) to Mar. 2026 ($105.32Mil).

Roivant Sciences's annual other current assets declined from Mar. 2024 ($236.88 Mil) to Mar. 2025 ($113.17 Mil) declined from Mar. 2025 ($113.17 Mil) to Mar. 2026 ($105.32 Mil).


Roivant Sciences Other Current Assets Related Terms


Roivant Sciences Other Current Assets Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Other Current Assets Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Assets
Get a 7-Day Free Trial 79.39 81.37 236.88 113.17 105.32

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.17 112.60 125.81 129.91 105.32
ROIV
55GF Score
Roivant Sciences Ltd ROIV
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $105.32 Mil mean?
Roivant Sciences (ROIV) has a Other Current Assets of $105.32 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Roivant Sciences.
Is Roivant Sciences' Other Current Assets too high?
Roivant Sciences' current Other Current Assets is $105.32 Mil. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Other Current Assets compare to RPRX and BNTX?
Roivant Sciences' Other Current Assets of $105.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Roivant Sciences. Roivant Sciences's current Other Current Assets is $105.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $34.73 — trading 232.3% above its estimated fair value. The current Other Current Assets is $105.32 Mil. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Other Current Assets is $105.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $34.73 is trading 232.3% above its estimated GF Value™ of $10.45. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Other Current Assets: $105.32 Mil
  • GF Value™: $10.45 vs. price of $34.73 (232.3% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIV

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.73
Price
$10.45
GF Value